Clinical trial
Evaluating the Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
NCT04261790 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluating the Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
- Lead sponsor
- Johns Hopkins University
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- August 1, 2020
- Completion date
- November 1, 2024
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.